Search results for "28"

showing 10 items of 3583 documents

The effect of immersion disinfection procedures on dimensional stability of two elastomeric impression materials

2008

The aim of this study was to determine the effect of immersion disinfection procedures on the dimensional stability of two elastomeric impression materials. Impressions of a stainless steel die were made with polyether (PE) and with additionpolymerized silicone rubber (PVS). The test specimens underwent disinfection treatment by immersion in two commercially available solutions containing quaternary ammonium compounds (Sterigum Powder, SP) and glutaraldehyde plus an amino derivative (MD520, MD), respectively. The impressions were measured at 4 different time points: before any disinfection treatment (T0); after the first disinfection (T1); 6 hours after the first disinfection (T2); after th…

medicine.medical_specialtyTime FactorsMaterials scienceSurface PropertiesDisinfectantDentistryimpression materials disinfectants dimensional stability disinfection polyether addition-polymerized siliconeElastomerSilicone rubberchemistry.chemical_compoundSettore MED/28 - Malattie OdontostomatologicheImmersionMaterials TestingmedicineImmersion (virtual reality)HumansGeneral Dentistrybusiness.industryDental Impression MaterialsDental DisinfectantsAmmonium compoundsSurgeryImpressionDisinfectionQuaternary Ammonium CompoundsResins SyntheticElastomerschemistryGlutaralSilicone ElastomersDental impression materialGlutaraldehydebusiness
researchProduct

Osteonecrosis of the jaws in patients assuming oral bisphosphonates for osteoporosis: A retrospective multi-hospital-based study of 87 Italian cases

2013

Abstract Background Bisphosphonates (BPs) are currently the chief drugs for the prevention/treatment of osteoporosis; one of their adverse effects is the osteonecrosis of the jaw (BRONJ). The primary endpoints of this multi-center cross-sectional study are: i) an observation of the clinical features of BRONJ in 87 osteoporotic, non-cancer patients; and ii) an evaluation of their demographic variables and comorbidities. Methods 87 BRONJ patients in therapy for osteoporosis with BPs from 8 participating clinical Italian centers were consecutively identified and studied. After BRONJ diagnosis and staging, comorbidities and data relating to local and drug-related risk factors for BRONJ were col…

medicine.medical_specialtyTime FactorsMultivariate analysisHeart DiseasesOsteoporosisSettore MED/50 - Scienze Tecniche Mediche ApplicateAdministration OralMandibleOsteonecrosis jawHospital based studyAdrenal Cortex HormonesRisk FactorsSettore MED/28 - Malattie OdontostomatologicheInternal medicineDiabetes MellitusInternal MedicinemedicineHumansIn patientRisk factorOral bisphopshonateAdverse effectOsteoporosis PostmenopausalAgedRetrospective StudiesAged 80 and overAlendronateBone Density Conservation AgentsDiphosphonatesbusiness.industryLiver DiseasesIncidence (epidemiology)Age FactorsMiddle Agedmedicine.diseaseSurgeryCross-Sectional StudiesItalyOral bisphopshonates; Osteonecrosis jaws; OsteoporosisHypertensionMultivariate AnalysisOsteoporosisBisphosphonate-Associated Osteonecrosis of the JawFemaleOsteonecrosis of the jawbusiness
researchProduct

Osteoporosis and bisphosphonates-related osteonecrosis of the jaw: Not just a sporadic coincidence-a multi-centre study

2011

Abstract Introduction Bisphosphonates (BPs) are powerful drugs that inhibit bone metabolism. Adverse side effects are rare but potentially severe such as bisphosphonate-related osteonecrosis of the jaw (BRONJ). To date, research has primarily focused on the development and progression of BRONJ in cancer patients with bone metastasis, who have received high dosages of BPs intravenously. However, a potential dilemma may arise from a far larger cohort, namely the millions of osteoporosis patients on long-term oral BP therapy. Patients and methods This current study assessed 470 cases of BRONJ diagnosed between 2004 and 2008 at eleven different European clinical centres and has resulted in the …

medicine.medical_specialtyTime FactorsSettore MED/09 - Medicina Internamedicine.medical_treatmentOral Surgical ProceduresOsteoporosisAdministration OralSettore MED/28 - Malattie OdontostomatologicheInternal medicinemedicineHumansMedical historyAdverse effectBone Density Conservation AgentsDiphosphonatesDose-Response Relationship Drugbusiness.industryContraindicationsOsteonecrosisBisphosphonatemedicine.diseaseSurgeryZoledronic acidOtorhinolaryngologyCohortOral and maxillofacial surgeryOsteoporosisSurgeryOral Surgeryosteoporosis bisphosphonates ostenecrosis jawsOsteonecrosis of the jawbusinessJaw Diseasesmedicine.drug
researchProduct

Juvenile central ossifying fibroma of the mandible: a case report

2010

Central ossifying fibroma is a rare fibro-osseous neoplasm in young children. It is highly aggressive and has a strong tendency to recur. We describe an 11-year-old girl with juvenile central ossifying fibromas of the mandible that caused obstruction of tooth eruption of the lower left second premolar. Oral examination revealed the presence of the primary lower left second molar and a small bony hard swelling over the left side of the mandibular body. After a computed tomographic scan, an incisional biopsy was performed, and the lesion proved to be a juvenile ossifying fibroma. Although this tumor often recurs early, and many authors suggest radical en bloc resection, we performed a more co…

medicine.medical_specialtyTooth eruptionMandibular nerveMandibular NeoplasmsTooth EruptionSettore MED/29 - Chirurgia MaxillofaccialeLesionMandibular second molarmandiblestomatognathic systemSettore MED/28 - Malattie OdontostomatologichemedicinePremolarSecondary PreventionHumansBicuspidChildbusiness.industryCentral ossifying fibromaMandibleGeneral Medicinemedicine.diseaseSurgerystomatognathic diseasesMandibular Neoplasmsmedicine.anatomical_structureTreatment OutcomePediatrics Perinatology and Child HealthFibroma OssifyingCentral fibroma ossifyingSurgeryFemalemedicine.symptombusinessTomography X-Ray Computedteeth eruption
researchProduct

What Is the Impact of Innovative Electronic Health Interventions in Improving Treatment Adherence in Asthma? The Pediatric Perspective

2019

Suboptimal adherence to treatment is a significant issue in the management of pediatric asthma and is a major cause of uncontrolled disease, life-threatening attacks, and increased utilization of healthcare resources. Electronic health (e-Health) solutions have the potential to positively impact asthma self-management in children and adolescents and their families, thereby improving treatment adherence and asthma outcomes. However, there is a lack of sufficient data to support widespread adoption of e-Health tools in pediatric asthma practice. A critical evaluation of the impact of these new interventions on treatment adherence in childhood asthma must consider unmet needs, heterogeneity of…

medicine.medical_specialtyTreatment adherencePsychological interventionMobile applicationDiseaseElectronic monitoring devicesPediatrics03 medical and health sciences0302 clinical medicineMobile applicationsInventionsAsthma controlHealth caremedicineHumansImmunology and Allergy030212 general & internal medicineChildIntensive care medicinemHealthChildrenAsthmaChildhood asthmabusiness.industryPerspective (graphical)medicine.diseaseQuality ImprovementTelemedicineAsthmaTreatment Adherence and ComplianceItaly030228 respiratory systemElectronic monitoring deviceAdherencee-Healthbusiness
researchProduct

Potential Diagnostic Properties of Chest Ultrasound in Thoracic Tuberculosis-A Systematic Review.

2018

Background: Chest ultrasound (CUS) has been shown to be a sensitive and specific imaging modality for pneumothorax, pneumonia, and pleural effusions. However, the role of chest ultrasound in the diagnosis of thoracic tuberculosis (TB) is uncertain. We performed a systematic search in the medical literature to better define the potential role and value of chest ultrasound in diagnosing thoracic tuberculosis. Aim: To describe existing literature with regard to the diagnostic value of chest ultrasound in thoracic tuberculosis. Methods: MEDLINE, EMBASE, and Scopus databases were searched for relevant articles. We included studies that used chest ultrasound for the diagnosis or management of any…

medicine.medical_specialtyTuberculosisPleural effusionlow-resource settingsHealth Toxicology and MutagenesisRadiographylcsh:MedicineReview03 medical and health sciences0302 clinical medicineBiopsyMedicineHumans030212 general & internal medicinetuberculosiUltrasonographylung ultrasoundmedicine.diagnostic_testbusiness.industryUltrasoundlcsh:RPublic Health Environmental and Occupational Healthmedicine.diseasePneumonia030228 respiratory systemPneumothoraxEffusiontuberculosisRadiologybusinessInternational journal of environmental research and public health
researchProduct

Chronic obstructive lung disease “expert system”: validation of a predictive tool for assisting diagnosis

2018

Fulvio Braido,1 Pierachille Santus,2 Angelo Guido Corsico,3 Fabiano Di Marco,4 Giovanni Melioli,5 Nicola Scichilone,6 Paolo Solidoro7 1Department of Internal Medicine, IRCCS San Martino di Genova University Hospital, Genoa, Italy; 2Department of Biomedical and Clinical Sciences, University of Milan, Division of Respiratory Diseases, “L. Sacco” University Hospital, ASST Fatebenefratelli-Sacco, Milan, Italy; 3Department of Internal Medicine and Therapeutics, Division of Respiratory Diseases, IRCCS Policlinico San Matteo Foundation, University of Pavia, Italy; 4Department of Health Sciences, University of Milan, San Paolo Hospital, Milan, Italy; 5Center for Precision Medici…

medicine.medical_specialtyValidation studyConcordance analysisbusiness.industryGeneral MedicinePrimary careInternational Journal of Chronic Obstructive Pulmonary Diseasemedicine.diseasecomputer.software_genreObstructive lung diseaseExpert system03 medical and health sciences0302 clinical medicine030228 respiratory systemSample size determinationConcomitantEmergency medicinemedicine030212 general & internal medicineMedical diagnosisbusinesscomputerInternational Journal of Chronic Obstructive Pulmonary Disease
researchProduct

Systematic Review and Meta-analysis of Pirfenidone, Nintedanib, and Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis.

2020

Background: The comparative efficacy of pirfenidone, nintedanib, and pamrevlumab in slowing the rate of forced vital capacity (FVC) decline and mortality in patients with idiopathic pulmonary fibrosis (IPF) is unknown. Objective: To perform a systematic review and meta-analysis (MA) of these drugs for IPF. Methods: We searched CENTRAL, PubMed, EMBASE, ClincalTrials.gov, and the World Health Organization’s registry databases up to March 2020. Phase II/III randomized controlled trials in adults with IPF were eligible. The random-effect model was implemented calculating the effect size and respective 95% CI as Cohen’s d for change from baseline FVC (in percentage predicted and liters) and odds…

medicine.medical_specialtyVital capacityIndolesPyridones03 medical and health scienceschemistry.chemical_compoundFEV1/FVC ratioIdiopathic pulmonary fibrosis0302 clinical medicineInternal medicinemedicineHumansPharmacology (medical)In patient030212 general & internal medicinebusiness.industryPirfenidonemedicine.diseaseIdiopathic Pulmonary FibrosisTreatment Outcome030228 respiratory systemchemistryMeta-analysisNintedanibbusinessAll cause mortalitymedicine.drugThe Annals of pharmacotherapy
researchProduct

Clinical Development of Mepolizumab for the Treatment of Severe Eosinophilic Asthma: On the Path to Personalized Medicine.

2021

The development of mepolizumab, an anti-IL-5 monoclonal antibody for the treatment of severe eosinophilic asthma, is an example of a clinical development program that evolved over time based on sound, basic scientific principles. Initial clinical data on the effects of mepolizumab on lung function in a general asthmatic population were disappointing. However, it became clear that mepolizumab may be more effective against other clinical endpoints, particularly asthma exacerbations, in patients with more severe disease. Furthermore, a developing understanding of asthma disease pathobiology led to the identification of an appropriate target population and predictive biomarker for mepolizumab t…

medicine.medical_specialty[SDV]Life Sciences [q-bio]PopulationDiseaseAntibodies Monoclonal Humanized03 medical and health sciences0302 clinical medicineClinical endpointImmunology and AllergyMedicineHumans030212 general & internal medicineAnti-Asthmatic AgentsPrecision MedicineIntensive care medicineAdverse effecteducationComputingMilieux_MISCELLANEOUSAsthmaeducation.field_of_studybusiness.industrymedicine.diseaseAsthmaEosinophils030228 respiratory systemAsthma Control QuestionnairePersonalized medicinebusinessMepolizumabmedicine.drugThe journal of allergy and clinical immunology. In practice
researchProduct

Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course

2019

Antisynthetase syndrome (ASSD) is a rare clinical condition that is characterized by the occurrence of a classic clinical triad, encompassing myositis, arthritis, and interstitial lung disease (ILD), along with specific autoantibodies that are addressed to different aminoacyl tRNA synthetases (ARS). Until now, it has been unknown whether the presence of a different ARS might affect the clinical presentation, evolution, and outcome of ASSD. In this study, we retrospectively recorded the time of onset, characteristics, clustering of triad findings, and survival of 828 ASSD patients (593 anti-Jo1, 95 anti-PL7, 84 anti-PL12, 38 anti-EJ, and 18 anti-OJ), referring to AENEAS (American and Europea…

medicine.medical_specialtyantisynthetase antibodies; antisynthetase syndrome; arthritis; interstitial lung disease; myositisantisynthetase syndrome; antisynthetase antibodies; arthritis; myositis; interstitial lung diseaseMedizinArthritislcsh:MedicineAntisynthetase syndromeInterstitial lung diseaseAntisynthetase syndromeArticleNO03 medical and health sciences0302 clinical medicineInternal medicinemedicineantisynthetase antibodiesantisynthetase antibodies antisynthetase syndrome arthritis interstitial lung disease myositisddc:610Myositis030203 arthritis & rheumatologyinterstitial lung diseaseAntisynthetase antibodiesbiologyMyositisbusiness.industryArthritislcsh:RInterstitial lung diseaseAutoantibodyGeneral Medicinemedicine.diseasearthriti030228 respiratory systemarthritisTime courseCohortbiology.proteinAntibodyantisynthetase syndromebusinessantisynthetase antibodiemyositis
researchProduct